1. Measuring Airway Remodeling in Patients With Different COPD Staging Using Endobronchial Optical Coherence Tomography
   Ming Ding et al, 2016, Chest CrossRef
2. Divergent epidermal growth factor receptor mutation patterns between smokers and non-smokers with lung adenocarcinoma
   Jeng-Sen Tseng et al, 2015, Lung Cancer CrossRef
3. Clinical and Metabolic Parameters in Non-Small Cell Lung Carcinoma and Colorectal Cancer Patients with and without KRAS Mutations
   Ahmet Yilmaz et al, 2014, International Journal of Environmental Research and Public Health CrossRef
4. First-line immunotherapy in non-small cell lung cancer: how to select and where to go
   Andrea Mogavero et al, 2023, Expert Review of Respiratory Medicine CrossRef
5. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma
   Antonio Calles et al, 2015, Clinical Cancer Research CrossRef
6. Differential expression of lung adenocarcinoma transcriptome with signature of tobacco exposure
   Raneem Y. Hammouz et al, 2020, Journal of Applied Genetics CrossRef
7. Mini Profile of Potential Anticancer Properties of Propofol
   Jing Song et al, 2014, PLoS ONE CrossRef
8. Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
   Luka Brcic et al, 2016, Diagnostic Pathology CrossRef
9. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland
   Alexandra Grosse et al, 2019, Diagnostic Pathology CrossRef
10. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma
    David J. H. Shih et al, 2020, Nature Genetics CrossRef
11. Inhibition of lung adenocarcinoma cells by insulin‐like growth factor‐I receptor and Kirsten rat sarcoma mutations: A mutation analysis with antisense oligodeoxynucleotide
    Shaoming Li et al, 2015, Thoracic Cancer CrossRef
12. Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer
    Marcel Wiesweg et al, 2019, Oncogene CrossRef
13. Characterizing the secretome of EGFR mutant lung adenocarcinoma
    Jennifer K. Luu et al, 2024, Frontiers in Oncology CrossRef
14. Variation in KRAS driver substitution distributions between tumor types is determined by both mutation and natural selection
    Sheli L. Ostrow et al, 2016, Scientific Reports CrossRef
15. Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet
    Yanjuan Xiong et al, 2017, Tumor Biology CrossRef
16. Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma
    Dhoha Dhieb et al, 2019, Cells CrossRef
17. Asbestos-Related lung Cancer: An underappreciated oncological issue
    Nico van Zandwijk et al, 2024, Lung Cancer CrossRef
18. Frequency and Spectrum of KRAS Mutations in Moroccan Patients with Lung Adenocarcinoma
    Ibrahim Elghissassi et al, 2014, ISRN Oncology CrossRef